<code id='2EF3541360'></code><style id='2EF3541360'></style>
    • <acronym id='2EF3541360'></acronym>
      <center id='2EF3541360'><center id='2EF3541360'><tfoot id='2EF3541360'></tfoot></center><abbr id='2EF3541360'><dir id='2EF3541360'><tfoot id='2EF3541360'></tfoot><noframes id='2EF3541360'>

    • <optgroup id='2EF3541360'><strike id='2EF3541360'><sup id='2EF3541360'></sup></strike><code id='2EF3541360'></code></optgroup>
        1. <b id='2EF3541360'><label id='2EF3541360'><select id='2EF3541360'><dt id='2EF3541360'><span id='2EF3541360'></span></dt></select></label></b><u id='2EF3541360'></u>
          <i id='2EF3541360'><strike id='2EF3541360'><tt id='2EF3541360'><pre id='2EF3541360'></pre></tt></strike></i>

          Home / comprehensive / focus

          focus


          focus

          author:explore    Page View:84

          Axovant Sciences(AXON) is the main event in biotech’s September cavalcade of clinical trial readouts, but while we wait, it’s a good idea to prep for important — and stock-moving — data releases from Zogenix(ZGNX) and Amicus Therapeutics(FOLD).

          Zogenix’s lead drug, called ZX008, is a low-dose liquid formulation of the old serotonin booster fenfluramine. The company is developing ZX008 to treat children with Dravet syndrome, a rare and severe type of epilepsy.

          advertisement

          You might remember fenfluramine as part of the “fen-phen” obesity regimen that was pulled from the market in 1997 because fenfluramine (at a higher dose) caused severe damage to people’s heart valves.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In